Post-authorisation studies are conducted after the medicinal product has been authorised in order to obtain more information about its safety, efficacy and overall benefit-risk profile in a real-world scenario, beyond the controlled environment of a clinical trial. Due to their nature, it often implies dealing with large datasets from different sources, so it is core for us to distill that information to produce well-organized and clear documents, while adhering to regulatory standards.